Skip to main content

01-03-2022 | Oncology | News | Article


EMA supports use of relugolix for prostate cancer

Author: Hannah Kitt

medwireNews: The EMA has recommended approval of relugolix for the treatment of advanced hormone-sensitive prostate cancer.

The positive opinion follows US FDA approval of relugolix in December 2020. Both decisions are based on findings from the phase 3 HERO trial in which the gonadotropin-releasing hormone antagonist achieved a medical castration rate of 96.7% in this patient population, which was superior to the rate of 88.8% with leuprolide acetate.

Relugolix will be available as 120 mg tablets.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group

Related topics